Ligandrol (LGD-4033)
Aliases: VK5211 · Ligandrol
Last verified: 2026-09-23
The short version
A potent SARM — Phase I/II show dose-dependent lean-mass gains; known for pronounced size. In development for hip fracture (VK5211). Status: in clinical trials. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A potent SARM — Phase I/II show dose-dependent lean-mass gains; known for pronounced size.
Mechanism of action
High-affinity AR agonist selective for muscle/bone.
Dosing & routes
Official / clinical context
No approved official document exists for Ligandrol (LGD-4033). Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 0.1–1 mg/day; community: 5–10 mg/day for 8 weeks. The community reports more pronounced fullness and mass than ostarine (visible within 3–4 weeks), with stronger suppression and occasional lethargy. A common "mini-bulk" choice.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The community reports more pronounced fullness and mass than ostarine (visible within 3–4 weeks), with stronger suppression and occasional lethargy. A common "mini-bulk" choice.
Protocol — official vs community
Official / label
No approved product. Phase 1/2 studied 0.1–1 mg daily; Phase 2 in healthy elderly at 1 mg showed dose-dependent effects and clinical-arrest signals in other programs.
- 01Study doses: 0.1–1 mg daily
Duration: Study-defined.
Stronger per-milligram than ostarine; the higher the dose, the harsher the suppression.
Community (anecdotal)
5–10 mg oral daily.
- Cycle:
- 8 weeks.
- Break:
- 8+ weeks with PCT.
The 5–10 mg community range is 5–10× study dosing; LGD-4033 is the SARM most associated with meaningful HPTA suppression.
Human evidence
Phase I/II (Viking): +1.2 kg lean mass at 1 mg/3 wks; Phase IIb for hip fracture.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Dose-dependent suppression, headache, lipid changes; rarely notable transaminase elevation.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.